MA34042B1 - Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf - Google Patents

Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Info

Publication number
MA34042B1
MA34042B1 MA34424A MA34424A MA34042B1 MA 34042 B1 MA34042 B1 MA 34042B1 MA 34424 A MA34424 A MA 34424A MA 34424 A MA34424 A MA 34424A MA 34042 B1 MA34042 B1 MA 34042B1
Authority
MA
Morocco
Prior art keywords
compounds
formulas
cancer
pyridines
pyrrolo
Prior art date
Application number
MA34424A
Other languages
Arabic (ar)
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Songyuan Shi
Guoxian Wu
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34042(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA34042B1 publication Critical patent/MA34042B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des composés (i) et des sels de ceux-ci, sur des formulations de ceux-ci, sur des conjugués de ceux-ci, sur des dérivés de ceux-ci, sur des formes de ceux-ci et sur leurs utilisations. Sous certains aspects et modes de réalisation, les composés décrits ou sels de ceux-ci, formulations de ceux-ci, conjugués de ceux-ci, dérivés de ceux-ci et formes de ceux-ci sont actifs sur chacune des protéines kinases braf et c-raf-1, et peuvent également être actifs sur l'une ou l'autre protéine kinase a-raf ou b-raf v600e ou sur les deux. L'invention porte également sur des procédés d'utilisation des composés pour traiter des maladies et des états pathologiques, tels qu'un mélanome, un cancer colorectal, un cancer de la thyroïde, un cancer de l'ovaire et un cancer du tractus biliaire.
MA34424A 2009-05-06 2010-05-04 Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf MA34042B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17605409P 2009-05-06 2009-05-06
PCT/US2010/033571 WO2010129567A1 (fr) 2009-05-06 2010-05-04 Pyrrolo [2, 3. b] pyridines qui inhibent la protéine kinase raf

Publications (1)

Publication Number Publication Date
MA34042B1 true MA34042B1 (fr) 2013-03-05

Family

ID=42236712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34424A MA34042B1 (fr) 2009-05-06 2010-05-04 Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Country Status (23)

Country Link
US (3) US8198273B2 (fr)
EP (2) EP2427433A1 (fr)
JP (2) JP2012526127A (fr)
KR (1) KR20140014386A (fr)
CN (1) CN102459262A (fr)
AR (1) AR076749A1 (fr)
AU (1) AU2010246005A1 (fr)
BR (1) BRPI1013843A2 (fr)
CA (1) CA2759997A1 (fr)
CL (1) CL2011002739A1 (fr)
CR (1) CR20110562A (fr)
EC (1) ECSP11011437A (fr)
IL (1) IL215908A0 (fr)
MA (1) MA34042B1 (fr)
MX (1) MX2011011737A (fr)
NI (1) NI201100189A (fr)
NO (1) NO20111508A1 (fr)
PE (1) PE20120518A1 (fr)
RU (1) RU2011149485A (fr)
SG (1) SG175810A1 (fr)
TW (1) TW201041888A (fr)
WO (2) WO2010129570A1 (fr)
ZA (1) ZA201108124B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
BR112012015745A2 (pt) * 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
WO2012106559A1 (fr) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarqueurs et leurs procédés d'utilisation
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9624213B2 (en) * 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) * 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
CA2828940C (fr) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combinaison de therapies immunomodulatrices locales et systemiques pour l'amelioration du traitement du cancer
WO2012138809A1 (fr) * 2011-04-05 2012-10-11 Dawei Zhang Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases
JP6113151B2 (ja) 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
ES2725790T3 (es) * 2011-08-26 2019-09-27 Neupharma Inc Algunas entidades químicas, composiciones, y métodos
CN102993199A (zh) * 2011-09-09 2013-03-27 山东轩竹医药科技有限公司 杂环取代的吡啶并吡咯激酶抑制剂
CN115403531A (zh) 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2806874B1 (fr) 2012-01-25 2017-11-15 Neupharma, Inc. Dérivés de quinoxaline-oxy-phenyl comme inhibiteurs de kinases
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6013029B2 (ja) * 2012-05-25 2016-10-25 千葉県 抗癌剤
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EA201590041A1 (ru) * 2012-07-03 2015-04-30 Ратиофарм Гмбх Твердая форма холиновой соли вемурафениба
DE102012016908A1 (de) * 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
EP2892534B8 (fr) 2012-09-06 2021-09-15 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
WO2014075077A1 (fr) * 2012-11-12 2014-05-15 Neupharma, Inc. Certaines entités chimiques, compositions et certains procédés
JP2016500076A (ja) * 2012-11-20 2016-01-07 プリンシピア バイオファーマ インコーポレイテッド Ｊａｋ３阻害剤としてのアザインドール誘導体
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
JP6199991B2 (ja) * 2013-01-18 2017-09-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ３置換ピラゾール及びｄｌｋ阻害剤としての使用
JP2016512518A (ja) * 2013-03-14 2016-04-28 ラシオファルム ゲーエムベーハー ベムラフェニブ塩酸塩の固体形態
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
WO2015075749A1 (fr) * 2013-11-22 2015-05-28 Laurus Labs Private Limited Nouveaux procédés de préparation de vemurafenib
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
NO2714752T3 (fr) * 2014-05-08 2018-04-21
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016164641A1 (fr) 2015-04-08 2016-10-13 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ES2913048T3 (es) 2015-09-21 2022-05-31 Opna Immuno Oncology Sa Compuestos heterocíclicos y usos de estos
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
EP3353164B1 (fr) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. 1,4-benzodiazepines bi-heteroaryl substituees et leurs utilisations pour le traitement du cancer
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
WO2017218544A1 (fr) * 2016-06-13 2017-12-21 Chemocentryx, Inc. Méthodes de traitement du cancer du pancréas
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
EP3558991A2 (fr) 2016-12-23 2019-10-30 Plexxikon Inc. Composés et procédés pour la modulation de cdk8, et indications associées
ES2928773T3 (es) * 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP2020511467A (ja) 2017-03-20 2020-04-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
AU2018307910B2 (en) 2017-07-25 2024-07-25 Daiichi Sankyo Company, Limited Formulations of a compound modulating kinases
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
TW202406538A (zh) * 2018-01-10 2024-02-16 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3768666A1 (fr) 2018-03-20 2021-01-27 Plexxikon Inc. Composés et procédés de modulation d'ido et de tdo, et indications pour ceux-ci
EP3810139A1 (fr) 2018-06-21 2021-04-28 HepaRegeniX GmbH Inhibiteurs de protéine kinase tricycliques pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
IL279641B2 (en) * 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
CA3164361A1 (fr) 2020-01-15 2021-07-22 Heparegenix Gmbh Derives de 3-benzoyl-1h-pyrrolo[2,3-b]pyridine utilises en tant qu'inhibiteurs de mkk4 pour le traitement de maladies du foie
WO2021222442A1 (fr) 2020-04-29 2021-11-04 Plexxikon Inc. Synthèse de composés hétérocycliques
JP2023530030A (ja) 2020-06-19 2023-07-12 シーフォー セラピューティクス， インコーポレイテッド Ｂｒａｆ分解剤
WO2025108405A1 (fr) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377318T3 (es) * 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
DE102005034406A1 (de) 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
GB0624084D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (fr) * 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications

Also Published As

Publication number Publication date
CA2759997A1 (fr) 2010-11-11
US20100286142A1 (en) 2010-11-11
EP2427462A1 (fr) 2012-03-14
BRPI1013843A2 (pt) 2016-04-12
AU2010246005A1 (en) 2011-12-01
CR20110562A (es) 2012-02-09
EP2427433A1 (fr) 2012-03-14
SG175810A1 (en) 2011-12-29
WO2010129567A1 (fr) 2010-11-11
JP2012526127A (ja) 2012-10-25
RU2011149485A (ru) 2013-06-20
ZA201108124B (en) 2014-04-30
ECSP11011437A (es) 2011-12-30
PE20120518A1 (es) 2012-05-24
NO20111508A1 (no) 2011-12-02
MX2011011737A (es) 2011-12-08
CN102459262A (zh) 2012-05-16
KR20140014386A (ko) 2014-02-06
CL2011002739A1 (es) 2012-04-09
US8198273B2 (en) 2012-06-12
NI201100189A (es) 2012-01-11
AR076749A1 (es) 2011-07-06
IL215908A0 (en) 2012-01-31
JP2012526128A (ja) 2012-10-25
TW201041888A (en) 2010-12-01
US20120122860A1 (en) 2012-05-17
US20120245174A1 (en) 2012-09-27
WO2010129570A1 (fr) 2010-11-11

Similar Documents

Publication Publication Date Title
MA34042B1 (fr) Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf
MX2015013945A (es) Derivados de urea utiles como inhibidores de quinasa.
ECSP109953A (es) Derivados de piridazinona
BRPI0815572A2 (pt) Compostos e composições como inibidores de quinases
EA201070667A1 (ru) 8-замещенные пиридо[2,3-в]пиразины и их применение
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
BR112015022011A2 (pt) derivados de imidazo[4,5-c]piridina e pirrolo[2,3-c] piridina como inibidores de ssao
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
UA97506C2 (xx) Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы
EA201691294A2 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
EA201100426A1 (ru) Бициклические ингибиторы киназы
UA111604C2 (uk) ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
WO2008121687A3 (fr) Composés imidazo[1,2-a]pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
MX342873B (es) Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
MX2009012709A (es) Derivados de arileter-piridazinona.
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
MX374552B (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero.